Background There is currently a paucity of data regarding clinical outcomes after everolimus-eluting stent (EES) implantation [compared to paclitaxel-eluting stents (PES) and sirolimus-eluting stents (SES)] in unselected patients with the…
Background The Zilver PTX stent with polymer-free paclitaxel coating is the first drug-eluting stent approved (currently CE marked, investigational in the United States and Japan) for the superficial femoral artery…
Background Both high on-treatment platelet reactivity and periprocedural myocardial infarction (MI) are associated with adverse events following percutaneous coronary intervention (PCI). The optimal method of quantifying platelet reactivity remains controversial….
Background Patients with lesions located in small vessels are at increased risk of adverse outcomes after PCI. Improved safety and efficacy have been previously demonstrated with XIENCE V stents in…
Hydrogen sulfide (H 2 S) is a novel gaseous signaling molecule that up-regulates antioxidants, anti-apoptogens, and promotes cellular survival. In the heart, cystathionine gamma-lyase (CSE) is the primary enzyme for…
Background Severe aortic stenosis (AS) patients with left ventricular ejection fraction (LVEF) <20% are currently excluded from transcatheter aortic valve implant trials and are believed to be at higher risk…
Background Stress-induced cardiomyopathy (SIC) is a novel syndrome increasingly recognized worldwide. Because the clinical presentation of SIC is very similar to acute coronary syndromes, the diagnosis is most frequently made…
Background Patients undergoing pacemaker and/or cardioverter–defibrillator (PM/ICD) implantation/upgrade might have difficult access due to sub/total central vein occlusions, usually related to prior venous manipulation. This study aimed to describe the…
Background The association between early discontinuation of clopidogrel after drug-eluting stent (DES) implantation and an increased risk of adverse cardiovascular events is well documented. However, little is known about the…
Background Drug-eluting bioabsorbable stents (DEBSs) represent a new device-based therapy for coronary artery disease. It has been reported that the stented segment becomes re-endothelialized after 1 month and the segments…
